Venture Capital Investment Trends in Pharma – Q3 2026
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report analyzes the venture capital (VC) investment activity in Q3 2026 in the Pharma sector.
Scope
This report provides an overview of VC investment activity globally in Q3 2026 in the Pharma sector involving biopharmaceutical drug companies.
It identifies key trends, and the most notable deals announced in Q3 2026 in the Pharma sector.
Key Highlights
In Q3 2026, Global pharma investment totalled $6.3 billion, down 33% from Q2 2026. Deal volume fell 18.5% quarter over quarter to 154 transactions. Oncology ranked as the top therapy area, with 70 deals backed by 273 investors.
Reasons to Buy
Companies that strategically invest in venture funding position themselves for success, while those that fail to adapt risk falling behind.
This report provides an overview of global VC investment trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Anew Labs
Encoded Therapeutics
Solstice Oncology
LifeMine Therapeutics
Celea Therapeutics
Biossil
Vaderis Therapeutics
Basecamp Research
Crystalys Therapeutics
Circle Pharma
InduPro
Claris Biotherapeutics
Expedition Therapeutics
Epicrispr Biotechnologies
Moonwalk Biosciences
Engine Biosciences
Sling Therapeutics
Innovent Biologics
Table of Contents
Table
Figures
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports